Examining the Clinical Effectiveness of Non-Carbapenem beta-Lactams for the Treatment of Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae

被引：2
作者：
Gibble, Allison M. [1 ,2 ]
Gross, Alan E. [3 ]
Huang, Angela M. [1 ,2 ]
机构：
[1] Froedtert, Dept Pharm, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60612 USA
来源：
ANTIBIOTICS-BASEL | 2015年 / 4卷 / 04期
关键词：
extended-spectrum beta-lactamases; piperacillin-tazobactam; cefepime; carbapenems;
D O I：
10.3390/antibiotics4040653
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Treatment options for extended-spectrum -lactamase-producing Enterobacteriaceae are limited. Piperacillin-tazobactam and cefepime represent potential alternative treatment options; however, large prospective studies are lacking. This review evaluates the current literature regarding use of piperacillin-tazobactam and cefepime for the treatment of extended-spectrum -lactamase-producing Enterobacteriaceae. Antimicrobial stewardship programs can play a key role in guiding the best practices for the management of these challenging infections.
引用
收藏
页码：653 / 666
页数：14
相关论文
共 41 条
  • [1] Treatment of Extended-Spectrum Beta-Lactamase Enterobacteriaceae With Cefepime: The Dose Matters, Too
    Altshuler, Jerry
    Aitken, Samuel L.
    Guervil, David
    Esaian, Diana
    Papadopoulos, John
    Arias, Cesar A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 57 (06) : 915 - 916
  • [2] Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations
    Andes, D
    Craig, WA
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 : 10 - 17
  • [3] [Anonymous], 2015, AVYCAZ CEFTAZIDIME A
  • [4] [Anonymous], 2015, ZERB CET TAZ PRES IN
  • [5] [Anonymous], 2014, M100S24 CLSI
  • [6] Emergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care Patients
    Armand-Lefevre, Laurence
    Angebault, Cecile
    Barbier, Francois
    Hamelet, Emilie
    Defrance, Gilles
    Ruppe, Etienne
    Bronchard, Regis
    Lepeule, Raphael
    Lucet, Jean-Christophe
    El Mniai, Assiya
    Wolff, Michel
    Montravers, Philippe
    Plesiat, Patrick
    Andremont, Antoine
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (03) : 1488 - 1495
  • [7] Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms
    Bhat, Sunil V.
    Peleg, Anton Y.
    Lodise, Thomas P., Jr.
    Shutt, Kathleen A.
    Capitano, Blair
    Potoski, Brian A.
    Paterson, David L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) : 4390 - 4395
  • [8] In vitro killing of parenteral beta-lactams against standard and high mocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae
    Burgess, DS
    Hall, RG
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (01) : 41 - 46
  • [9] Prevalence of β-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 US Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010)
    Castanheira, Mariana
    Farrell, Sarah E.
    Deshpande, Lalitagauri M.
    Mendes, Rodrigo E.
    Jones, Ronald N.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) : 3012 - 3020
  • [10] Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
    Chopra, Teena
    Marchaim, Dror
    Veltman, Jennifer
    Johnson, Paul
    Zhao, Jing J.
    Tansek, Ryan
    Hatahet, Dania
    Chaudhry, Khawar
    Pogue, Jason M.
    Rahbar, Hiro
    Chen, Ting-Yi
    Thientu Truong
    Rodriguez, Victor
    Ellsworth, Joseph
    Bernabela, Luigino
    Bhargava, Ashish
    Yousuf, Adnan
    Alangaden, George
    Kaye, Keith S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (07) : 3936 - 3942
12345